Summary:
- The article discusses the use of PSMA PET-CT imaging to assess the response to therapy in patients with metastatic renal cell carcinoma (mRCC).
- PSMA PET-CT is a novel imaging technique that can detect prostate-specific membrane antigen (PSMA), which is expressed in various types of cancer, including mRCC.
- The findings presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium suggest that PSMA PET-CT may be a valuable tool for monitoring the response to treatment in patients with mRCC, potentially improving patient outcomes.